Clinical Scorecard: Screening for Pancreatic Cancer in Patients with Newly Diagnosed or Worsening Diabetes: Initial Findings from the PANDOME Trial

At a Glance

Key Highlights

• New-onset diabetes (NOD) in individuals ≥50 years increases pancreatic cancer risk 6- to 8-fold; deteriorating diabetes (DD) may also be a risk factor.
• PANDOME study prospectively screened 109 individuals (97 NOD, 12 DD) using MRI/MRCP, detecting one stage 1 pancreatic ductal adenocarcinoma in the DD group (0.9% detection rate).
• Endocrinologists are key referral sources for DD patients; inclusion of DD cohort is supported for future pancreatic cancer screening studies.

Guideline-Based Recommendations

Diagnosis

• Screen individuals ≥50 years with new-onset diabetes or deteriorating diabetes using contrast-enhanced MRI/MRCP.
• Classify MRI findings as normal, benign-abnormal, suspicious, or incidental to guide further evaluation.
• Consider pancreas biopsy for suspicious imaging findings.

Management

• Refer patients with suspicious MRI findings for biopsy and further oncologic evaluation.
• Engage endocrinologists in referral pathways for patients with deteriorating diabetes.
• Monitor glycemic indices and weight changes to identify candidates for screening.

Monitoring & Follow-up

• Perform anxiety and depression assessments during screening to monitor patient well-being.
• Track hemoglobin A1c levels and insulin requirements to detect deteriorating diabetes.
• Follow-up on incidental and benign pancreatic abnormalities to ensure safety.

Risks

• Low detection rate of early-stage pancreatic cancer (0.9%) in screened population.
• No safety signals observed from benign pancreatic abnormalities or incidental findings.
• Potential anxiety related to screening necessitates psychological monitoring.

Patient & Prescribing Data

Individuals aged ≥50 years with new-onset or deteriorating diabetes undergoing pancreatic cancer screening

Deteriorating diabetes patients showed higher HbA1c, greater weight loss, and increased insulin requirements compared to new-onset diabetes, indicating a distinct high-risk subgroup for pancreatic cancer screening.

Clinical Best Practices

• Include both new-onset and deteriorating diabetes cohorts in pancreatic cancer screening protocols.
• Utilize MRI/MRCP as a non-invasive imaging modality for early detection in high-risk diabetic populations.
• Engage endocrinologists actively in identifying and referring patients with deteriorating diabetes for pancreatic cancer screening.
• Provide free and accessible screening services to improve recruitment and adherence.
• Incorporate psychological assessments to address anxiety and depression related to screening procedures.

References

• PANDOME Trial ClinicalTrials.gov Registration
• Cancer of the Pancreas Screening Study
• Pancreatic Cancer Early Detection Consortium